Givosiran

吉伏司瑞

Report date: 2024/06/06 11:03:13
NMEFirst In Class

Base Information

Drug NameGivosiran
Drug Alias NameGivlaariALN-AS1
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interference5 aminolevulinate synthase 1 inhibitors
Targets5 aminolevulinate synthase 1
Therapy Area/IndicationsPorphyriasPorphyria, VariegatePorphyria, Acute Intermittent +[5] 
Global Approved IndicationsPorphyria, Acute IntermittentPorphyrias, Hepatic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/20
Country/TerritoryBulgariaCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAlnylam Japan KkAlnylam Netherlands BvAlnylam Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsPorphyriasPorphyria, VariegatePorphyria, Acute Intermittent +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeJ05AB
Related LinksWikipediaDrugBankKEGG